This virus therapy supercharges the immune system against brain cancer
Why it matters: This therapy offers a new hope for glioblastoma patients, transforming untreatable tumors into targets for the immune system.
- Mass General Brigham and Dana-Farber Cancer Institute researchers developed an oncolytic virus, a modified herpes simplex virus, that specifically targets and replicates within glioblastoma cells, leaving healthy tissue unharmed.
- The therapy not only directly destroys tumor cells but also activates and recruits immune T cells deep into the brain tumors, a crucial step for glioblastoma which typically lacks immune infiltration.
- A phase 1 clinical trial involving 41 patients with recurrent glioblastoma demonstrated that treatment with the virus was associated with longer survival, particularly in patients who already possessed antibodies against the virus.
- Analysis of tumor samples revealed that patients with cytotoxic T cells located closer to dying tumor cells experienced longer survival, indicating a direct link between the immune response and therapeutic benefit.
Scientists at Mass General Brigham and Dana-Farber Cancer Institute have engineered a modified herpes virus that, with a single injection, can invade glioblastoma cells, kill them, and supercharge the immune system to attack the aggressive brain cancer. This breakthrough therapy has shown a link to longer survival in patients by transforming 'cold' tumors into 'hot' ones, drawing and sustaining cancer-fighting immune cells deep within the tumor.
